Catheter-delivered clot-dissolving medicine versus blood thinners for serious pulmonary embolism
Compares two treatments in adults with acute pulmonary embolism at intermediate-high risk.
Key facts
- Who runs it
- Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
- Where
- Russia1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Evaluation of the Standard Catheter-directed Thrombolysis Effectiveness in Intermediate-High-Risk Pulmonary Embolism Patients
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 10 Jan 2024
- Expected to end
- Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Standard Catheter-Directed Low Dose Thrombolysis
- Standard Anticoagulation
- Record updated
- 5 July 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a recent, intermediate-high-risk blood clot in the lung arteries (pulmonary embolism). It compares low-dose alteplase given through a catheter with standard blood thinners.
- Age
- Older than 18 years.
- Sex
- All sexes can join.
- Disease stage
- Intermediate-high-risk pulmonary embolism in the main or lobar lung arteries, confirmed by CT angiography. Symptoms started less than 14 days ago. The right heart chamber must be strained (RV/LV diameter ratio >1 on heart ultrasound or CT).
- Biomarker or test result
- Raised hs-troponin or NT-proBNP in the blood.
Main reasons for not taking part
- High-risk pulmonary embolism, or a blood clot inside the heart chambers.
- Reasons clot-dissolving drugs cannot be used, such as past brain bleeding, stroke or recent major bleeding, surgery or injury.
- Haemoglobin below 70 g/L or platelet count of 100 x 109 or less.
- Allergy to alteplase, UFH or contrast dye.
- Pregnancy, breastfeeding, or a clinically significant cancer.
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age > 18 years
- Computed tomography angiography (CTA) - verified proximal (pulmonary trunk and/or main and/or lobar branches of the pulmonary artery) PE and symptom onset < 14 days prior
- Intermediate-high risk PE with a RV dysfunction (RV/LV diameter ratio >1 on TTE or CTA) and an elevated biomarker (hs-troponin or NT-proBNP) level
- Signed informed consent
Who cannot take part
- Absolute contraindications for the use of thrombolytic therapy: history of hemorrhagic stroke or stroke of unknown etiology; ischemic stroke or transient ischemic attack within the last 6 months; extensive bleeding currently or within the previous 6 months, hemorrhagic diathesis; diseases of the central nervous system (including neoplasms, aneurysm, surgery on the brain or spinal cord); intracranial (including subarachnoid) hemorrhage currently or in history, suspicion of hemorrhagic stroke; severe uncontrolled arterial hypertension; major surgery or major trauma within the previous 3 months, recent traumatic brain injury; labor during the previous 10 days; severe liver diseases, including liver failure, cirrhosis, portal hypertension (including esophageal varices) and active hepatitis; bacterial endocarditis, pericarditis; acute pancreatitis; confirmed peptic ulcer of the stomach or duodenum within the last 3 months; arterial aneurysms, congenital anomalies of arteries/veins
- Thrombus in the heart chambers on TTE
- Allergic to alteplase or UFH or contrast allergy
- Clinically significant malignancies
- Haemoglobin level < 70 g/L, platelet count ≤ 100 x 109
- High-risk pulmonary embolism
- Pregnant or breastfeeding
This trial is currently available in Russia.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A single-center, open-label, randomized comparative study of two treatment strategies in patients with intermediate-high-risk acute pulmonary embolism (PE). Patients will be randomized in a 1:1 ratio to standard anticoagulant therapy or standard catheter-directed thrombolysis (SСDT) with a low dose of alteplase, followed by evaluation of short- and long-term efficacy and safety in each group
The 2 groups in the trial
- Standard Catheter-Directed ThrombolysisTreatment being tested
Local, standard catheter-directed thrombolysis with a total alteplase dose of 10 mg (for unilateral lesion) or 20 mg (for bilateral lesion) administered over 9 hours
Treatment: Standard Catheter-Directed Low Dose Thrombolysis
- Standard AnticoagulationExisting treatment, for comparison
Therapy with UFH with targeted аPTT lasts for 24 hours (no more than 48 hours in total). Then the change to oral anticoagulants is performed.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of the Standard Catheter-directed Thrombolysis (SCDT) Effectiveness in Intermediate-High-Risk Pulmonary Embolism Patients
- Plain-language title
- Catheter-delivered clot-dissolving medicine versus blood thinners for serious pulmonary embolismGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 5 July 2024